Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBIT: 2019-2025

Historic EBIT for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Sep 2025 value amounting to $65.5 million.

  • Harmony Biosciences Holdings' EBIT rose 6.12% to $65.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.6 million, marking a year-over-year increase of 28.72%. This contributed to the annual value of $190.8 million for FY2024, which is 0.63% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its EBIT stood at $65.5 million for Q3 2025, which was up 35.92% from $48.2 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' EBIT peaked at $65.5 million during Q3 2025, and registered a low of $11.9 million during Q3 2022.
  • Moreover, its 3-year median value for EBIT was $52.0 million (2024), whereas its average is $50.3 million.
  • In the last 5 years, Harmony Biosciences Holdings' EBIT surged by 442.05% in 2023 and then tumbled by 54.47% in 2024.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' EBIT stood at $28.6 million in 2021, then soared by 66.30% to $47.6 million in 2022, then decreased by 15.58% to $40.2 million in 2023, then soared by 38.64% to $55.7 million in 2024, then increased by 6.12% to $65.5 million in 2025.
  • Its EBIT was $65.5 million in Q3 2025, compared to $48.2 million in Q2 2025 and $56.2 million in Q1 2025.